ELIMINATION OF HEPATITIS C AMONG HEMODIALYSIS PATIENTS IN ALAGOAS, BRAZIL

Introduction and Objectives

Hepatitis C virus (HCV) infection remains a major global public health concern. The World Health Organization (WHO) aims to eliminate it the disease by 2030 through integrated prevention, diagnosis, and treatment strategies. In Brazil, most the majority of hepatitis-related deaths are due attributed to HCV. Transmission is parenteral occurs primarily through parenteral exposure; high-risk groups include individuals receiving blood transfusions. Hemodialysis patients are particularly vulnerable.

To characterize and establish a systematic registry of HCV-infected hemodialysis patients in Alagoas, Brazil, with the aim to eliminate HCV through antiviral therapy.

Materials and Methods

A prospective study was conducted from April 2023 to December 2024, including HCV-positive patients undergoing renal replacement therapy at ten hemodialysis units in Alagoas.

Results

A total of 44 patients were included (14 female, and 30 male). Eleven had achieved spontaneous viral clearance; and four died. Twenty-eight patients underwent a 12-week course of Glecaprevir/Pibrentasvir, all achieving sustained virologic response. Consequently, HCV was eliminated in all participating dialysis units.

Conclusions

Alagoas is the first Brazilian state to eradicate HCV from all dialysis units, representing a notable public health milestone. Continued and expanded targeted strategies are essential to eliminate HCV in other high-risk groups.

Conflict of interest: None